Brokers Offer Predictions for NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Intellia Therapeutics in a research report issued to clients and investors on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will post earnings per share of ($4.87) for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

A number of other brokerages also recently commented on NTLA. Chardan Capital dropped their price objective on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Wells Fargo & Company dropped their target price on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. BMO Capital Markets lowered their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Barclays cut their target price on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright initiated coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 price target for the company. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Stock Performance

NTLA stock opened at $8.73 on Monday. The company’s 50 day moving average price is $10.05 and its 200 day moving average price is $13.97. The firm has a market capitalization of $903.70 million, a price-to-earnings ratio of -1.60 and a beta of 1.97. Intellia Therapeutics has a fifty-two week low of $8.30 and a fifty-two week high of $28.23.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders sold 29,000 shares of company stock valued at $352,551. Insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently bought and sold shares of the company. Capstone Investment Advisors LLC boosted its holdings in shares of Intellia Therapeutics by 1.4% in the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock valued at $1,256,000 after acquiring an additional 831 shares in the last quarter. Ensign Peak Advisors Inc increased its holdings in shares of Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after purchasing an additional 1,100 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Intellia Therapeutics by 10.3% in the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Intellia Therapeutics by 14.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock worth $157,000 after buying an additional 1,582 shares in the last quarter. Finally, Arizona State Retirement System grew its position in Intellia Therapeutics by 6.1% during the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after buying an additional 1,615 shares during the period. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.